EADV 2025 News: Evommune, Inc.’s EVO756 Shows Robust and Rapid Improvement in CindU Patients
Evommune, Inc.’s EVO756 continues to show promise in adults with chronic inducible urticaria (CIndU), according to new Phase 2 data presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress in Paris, France.